Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4636103 | 0.99 | PGR (0.55) | PGROPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL31149456 | 0.92 | PGR (0.61) | PGROPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL11097820 | 0.89 | OPRM1 (0.60) | PGROPRM1HTR1AADRA2ADRD2 | |
| SCHEMBL4648870 | 0.89 | PGR (0.54) | PGROPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL8241559 | 0.84 | OPRM1 (0.49) | PGROPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL4647088 | 0.84 | CHRM2 (0.47) | PGROPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL4647996 | 0.84 | CHRM1 (0.65) | PGROPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL8241564 | 0.83 | OPRM1 (0.46) | PGROPRM1CHRM1DRD2 | |
| Hydrochloric Acid SCHEMBL4749245 | 0.83 | CHRM1 (0.64) | PGROPRM1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL4647887 | 0.83 | OPRM1 (0.48) | PGROPRM1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288412-B2 | Psychological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288412-B2 | Psychological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| EP-1960389-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| WO-2009124883-A1 | NOVEL 1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124882-A1 | NOVEL PIPERIDINYL-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-10-15 | — | — | WO | disclosed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| WO-2007036718-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | CHRM1, CHRM2, CHRM5 | PGR 807/4885OPRM1 14/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.